...
首页> 外文期刊>International Journal of Pharmaceutics >Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt.
【24h】

Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt.

机译:通过使用含有胆汁盐的脂质体,水溶性差的非诺贝特药物的生物利用度提高。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The main purpose of this study was to evaluate oral bioavailability of the poorly water-soluble drug fenofibrate when liposomes containing a bile salt were used as oral drug delivery systems. Liposomes composed of soybean phosphotidylcholine (SPC) and sodium deoxycholate (SDC) were prepared by a dry-film dispersing method coupled with sonication and homogenization. Several properties of the liposomes, including particle size, entrapment efficiency and membrane fluidity, were extensively characterized. In vitro release experiments indicated that no more than 20% of total fenofibrate was released from SPC/cholesterol (CL) and SPC/SDC liposomes at 2 h, in contrast with near complete release for micronized fenofibrate capsules. Strikingly, in vivo measurements of pharmacokinetics and bioavailability demonstrated higher rates of fenofibrate absorption from both SPC/SDC and SPC/CL liposomes than micronized fenofibrate. The bioavailability of SPC/SDC and SPC/CL liposomes was 5.13- and 3.28-fold higher, respectively, than that of the micronized fenofibrate. The disparity between oral bioavailability and in vitro release for liposomes strongly suggests alternative absorption mechanisms rather than enhanced release. Importantly, SPC/SDC liposomes exhibited a 1.57-fold increase in bioavailability relative to SPC/CL liposomes, indicating that liposomes containing bile salts may be used to enhance oral bioavailability of poorly water-soluble drugs.
机译:这项研究的主要目的是评估当使用含胆汁盐的脂质体作为口服药物递送系统时,水溶性差的非诺贝特药物的口服生物利用度。通过干膜分散法,超声处理和均质化,制备了由大豆磷脂酰胆碱(SPC)和脱氧胆酸钠(SDC)组成的脂质体。脂质体的几种性质,包括粒径,包封率和膜流动性,已得到广泛表征。体外释放实验表明,在2 h时,SPC /胆固醇(CL)和SPC / SDC脂质体释放的总非诺贝特含量不超过20%,而微粉化的非诺贝特胶囊几乎完全释放。令人惊讶的是,体内药代动力学和生物利用度测量显示,与微粉化非诺贝特相比,SPC / SDC和SPC / CL脂质体吸收非诺贝特的比率更高。 SPC / SDC和SPC / CL脂质体的生物利用度分别比微粉非诺贝特高5.13倍和3.28倍。口服生物利用度与脂质体的体外释放之间的差异强烈暗示了替代的吸收机制,而不是增强的释放。重要的是,相对于SPC / CL脂质体,SPC / SDC脂质体的生物利用度提高了1.57倍,这表明含有胆汁盐的脂质体可用于增强水溶性差的药物的口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号